

# AMCoR

Asahikawa Medical University Repository <http://amcor.asahikawa-med.ac.jp/>

Molecular carcinogenesis (2017.2) 56(2):478–488.

Role of the BrafV637E mutation in hepatocarcinogenesis induced by treatment with diethylnitrosamine in neonatal B6C3F1 mice

Yamamoto M, Tanaka H, Xin B, Nishikawa Y, Yamazaki K, Shimizu K, Ogawa K.

# Role of the *BrafV637E* Mutation in Hepatocarcinogenesis Induced by Treatment With Diethylnitrosamine in Neonatal B6C3F1 Mice

Masahiro Yamamoto,<sup>1</sup> Hiroki Tanaka,<sup>2</sup> Bing Xin,<sup>1</sup> Yuji Nishikawa,<sup>1</sup> Kosuke Yamazaki,<sup>3</sup> Keiko Shimizu,<sup>2</sup> and Katsuhiko Ogawa<sup>1\*</sup>

<sup>1</sup>Department of Pathology, Asahikawa Medical University, Asahikawa, Japan

<sup>2</sup>Department of Forensic Medicine, Asahikawa Medical University, Asahikawa, Japan

<sup>3</sup>Department of Clinical Medicine, Surgery Area, Japanese Red Cross Hokkaido College of Nursing, Kitami, Japan

The *BrafV637E* mutation is frequently reported in mouse hepatic tumors, depending on the mouse strain, and corresponds to the human *BrafV600E* mutation. In this study, we detected the *BrafV637E* mutation by whole-exome analysis in 4/4 hepatic tumors induced by neonatal treatment with diethylnitrosamine (DEN) in male B6C3F1 mice. We also detected the *BrafV637E* mutation in 54/63 (85.7%) hepatic lesions, including microscopic foci and grossly visible tumors, by PCR-direct sequencing. Although the mutation was detected in 5/7 (71.4%) hepatic tumors induced by neonatal DEN treatment followed by repeated CCl<sub>4</sub> administration, it was not detected in 24 tumors induced by CCl<sub>4</sub> treatment without DEN or in eight spontaneous lesions in B6C3F1 mice, suggesting that the mutation is induced by the genotoxic action of DEN. The DEN-induced tumors exhibited hyperphosphorylation of ERK1 and Akt, suggesting that the *BrafV637E* mutation might activate the MAPK and Akt pathways. Moreover, the DEN-induced tumors overexpressed mRNAs for the oncogene-induced senescence (OIS) markers such as p15<sup>Ink4b</sup> and p19<sup>Arf</sup> as well as pro-survival/pro-proliferative cytokines/chemokines such as complement C5/C5a, ICAM-1, IL-1 receptor antagonist and CXCL9, suggesting that the *BrafV637E* mutation influences the expression of genes involved in either OIS or cellular growth/survival. Liver-specific expression of mutated *Braf* under control of the albumin enhancer/promoter resulted in an enlarged liver that consisted entirely of small basophilic hepatocytes resembling DEN-induced preneoplastic hepatocytes with ERK1/Akt hyperphosphorylation and C5/C5a overexpression. These results indicate that the *BrafV637E* mutation induces hepatocytic changes in DEN-induced hepatic tumors. © 2016 The Authors. *Molecular Carcinogenesis* published by Wiley Periodicals, Inc.

Key words: whole-exome analysis; hepatic tumors; intracellular signaling; cytokines/chemokines; *BrafV600E* transgenic mice

## INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer death worldwide [1]. Many rodent hepatocarcinogenesis models have been developed to investigate the pathogenesis of HCC, to perform risk assessments of food/nutrition and to evaluate the effects of therapeutic agents. Diethylnitrosamine (DEN) is often used to induce hepatocarcinogenesis in rodents. Delivering a single low dose of DEN to neonatal mice results in the development of HCC without any further treatment [2]. In this model, foci of cellular alterations are observed in the early stage of hepatocarcinogenesis, and in the late stages, adenomas and HCC develop.

The mutational changes associated with chemically induced hepatocarcinogenesis depend not only on the carcinogens used but also on the species, strain, age and gender of the animals [3]. Buchmann et al. [4] have reported that in the hepatic tumors induced by neonatal treatment with DEN or 7, 12-dimethylbenz(a)anthracene, the *H-ras* codon 61 mutation is more prevalent in hepatocarcinogenesis-susceptible strains such as C3H mice, whereas the *BrafV637E* mutation is more prevalent in resistant strains such as C57BL/6,

indicating that either mutation may be selected depending on the genetic background.

The mouse *BrafV637E* mutation corresponds to the human *BrafV600E* mutation, which is frequently detected in certain human cancers, including melanoma and thyroid, ovarian and colon cancers [5]. In this study, we determined that the *BrafV637E* mutation is very common in hepatic lesions induced by neonatal DEN treatment in male B6C3F1 mice.

[The copyright line for this article was changed on 17 June 2016 after original online publication.]

Abbreviations: DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; OIS, oncogene-induced senescence; ICAM-1, intercellular adhesion molecule-1; IL-1ra, interleukin 1 receptor antagonist.

Conflict of interest: The authors declare no conflict of interest.

Grant sponsor: Japanese Ministry of Education, Culture, Sports, Science, and Technology; Grant sponsor: Asahikawa Medical University Advanced Science Research Program

\*Correspondence to: Katsuhiko Ogawa, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, Japan.

Received 11 December 2015; Revised 21 May 2016; Accepted 31 May 2016

DOI 10.1002/mc.22510

Published online 10 June 2016 in Wiley Online Library (wileyonlinelibrary.com).

However, the frequency of the *Braf* mutation in hepatocarcinogenesis induced by agents other than DEN and the changes induced by the *Braf* mutation in hepatocytes, particularly with respect to intracellular signaling and gene expression, have not been well studied. We therefore investigated (i) whether this mutation is specific to the DEN-induced model, (ii) how the *Braf*V637E mutation might provide a selective advantage to the mutated cells, and (iii) whether liver-specific expression of mutated *Braf* using an albumin enhancer/promoter causes phenotypic changes resembling those of DEN-induced hepatic tumors.

## MATERIALS AND METHODS

### Carcinogenic Treatment

Male B6C3F1 mice, which are commonly used for DEN-induced hepatocarcinogenesis [2] and to assess the carcinogenicity of chemicals [6], were generated by mating female C57BL/6J and male C3H/HeJ mice (CLEA Japan, Tokyo, Japan). One group of mice was intraperitoneally injected with DEN at a dose of 5  $\mu$ g/g body weight at 2 wk of age, and was fed a normal chow diet thereafter. The mice were sacrificed at 5, 8, and 13 months (Table 1). The second group was subcutaneously injected with CCl<sub>4</sub> (1 ml/kg body weight) three times weekly beginning at 8 wk of age and was sacrificed at 6 months (Table 2). The third group was treated first with DEN (5  $\mu$ g/g body weight) at 2 wk of age and then with intraperitoneal CCl<sub>4</sub> injections twice weekly starting at 4 wk and was sacrificed at 6 months after the start of CCl<sub>4</sub> treatment (Table 2). Spontaneous hepatic lesion samples isolated from 20-month-old male B6C3F1 mice were kindly provided by Dr. Takuji Tanaka (Tokai Cell Institute). Grossly visible tumors were isolated, frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$  until use. Microscopic foci were microdissected from 4- $\mu$ m-thick paraffin sections using a 27-gauge needle under microscopic observation. Livers of age-matched untreated mice were used as controls. All experimental procedures performed on mice were approved by the Asahikawa Medical University animal experiment committee on the basis of the guidelines for the humane care and protection of animals.

### Generation of Alb-Cre/*Braf*V600E Mice

Homozygous male *Braf*V600E mice (B6.129P2(Cg)-Braftm1Mmcm>J) reported by Dankort et al. [7] were

purchased from Jackson Laboratories (Bar Harbor, ME). In these mice, a LoxP-flanked cassette containing the human *Braf* exon 15–18 cDNA, mouse *Braf* polyadenylation sequences and neo gene is inserted into the mouse *Braf* intron 14 upstream of the human *Braf* exon 15 cDNA encoding the *Braf*V600E mutation. Alb-Cre/*Braf*V600E mice were produced by in vitro fertilization using heterozygous female Alb-Cre (Jackson Laboratories) and homozygous male *Braf*V600E mice. The hepatic expression of the transgene was investigated by RT-PCR and direct sequencing. Twenty male and 20 female Alb-Cre/*Braf*V600E mice were generated.

### Whole-Exome Analysis

DNA was extracted from the DEN-induced hepatic tumors and age-matched normal liver samples and then purified using a DNeasy Blood and Tissue Kit (Qiagen, Netherlands). For hepatic tumors, non-parenchymal cells were removed before DNA extraction as follows: the livers containing the DEN-induced tumors were perfused with collagenase solution, and the tumors (5–10 mm in diameter) were removed, minced with scissors, and passed through a 100- $\mu$ m cell strainer (BD Biosciences, San Jose, CA). The tumor cells were collected by low-speed centrifugation (90g for 1 min) and washed twice with phosphate-buffered saline (PBS). After a quality check of the DNA using a Qubit Fluorometer (Thermo Fisher Scientific, Waltham, MA), the exons were enriched by using an Agilent SureSelect Mouse All Exon kit (Agilent Technologies, Santa Clara, CA), and this was followed by sequencing on a HiSeq 2000 sequencer (Illumina, San Diego, CA). The mutations were analyzed within the exon regions with more than 100-fold coverage.

### PCR or RT-PCR and Direct Sequencing

For grossly visible tumors, DNA was extracted from frozen materials with a DNeasy Blood and Tissue Kit. For microscopic foci, DNA was extracted from microdissected samples with a DEXPAT kit (Takara Bio, Japan). The nomenclature of microscopic foci followed the criteria of the International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice [8]. The region that included the *Braf* codon 637 was amplified by PCR using appropriate primers (forward: 5'-gacctcagtgtaaaataggtgac, reverse: 5'-gcaattatgctggcttaca) and Mighty Amp DNA Polymerase (Takara Bio). Total RNA was extracted from frozen liver tissues of normal C57BL/6J and Alb-Cre/*Braf*V600E mice with Sepasol (Nacalai Tesque, Japan) and was reverse-transcribed with a cDNA Synthesis Kit (Roche, Basel, Switzerland). The region that included the *Braf* codon 637 was amplified from the cDNA samples by PCR using primers (forward: 5'-acttacagccaagtcaatc, reverse: 5'-gcatacacgtctgactgaaag) corresponding to the mouse *Braf* exons 14 and 16, respectively. The PCR products were purified with ExoStar (GE Healthcare, United

Table 1. Incidence of *Braf*V637E Mutation in DEN-Induced Lesions

| Age (months) | No. mice | Foci          | Tumors <sup>a</sup> |
|--------------|----------|---------------|---------------------|
| 5            | 7        | 16/18 (88.8%) | —                   |
| 8            | 3        | 22/28 (78.5%) | —                   |
| 13           | 3        | —             | 16/17 (94.1%)       |

<sup>a</sup>Histological type, not determined.

Table 2. Incidence of *BrafV637E* Mutation in Spontaneous, and  $\text{CCl}_4$  or DEN/ $\text{CCl}_4$ -Induced Lesions

| Lesions               | Age (months) | No. mice | <i>BrafV637E</i> no. lesions | Histological types |     |
|-----------------------|--------------|----------|------------------------------|--------------------|-----|
|                       |              |          |                              | Foci               | HCC |
| Spontaneous           | 20           | 6        | 0/8 (0%)                     | 6                  | 2   |
| $\text{CCl}_4^a$      | 6            | 16       | 0/24 (0%)                    | —                  | —   |
| DEN/ $\text{CCl}_4^a$ | 6            | 3        | 5/7 (71.4%)                  | —                  | —   |

<sup>a</sup>Histological type, not determined.

Kingdom) and sequenced using a BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific) on an Applied Biosystems 3500 Genetic Analyzer (Thermo Fisher Scientific).

#### Quantitative Real-Time PCR (qRT-PCR)

To quantify the  $p15^{\text{Ink4b}}$  and  $p19^{\text{Arf}}$  mRNA, RNA was extracted from DEN-induced hepatic tumors and age-matched normal livers. cDNA synthesized as described above was used in qRT-PCR reactions with incorporation of LightCycler RNA Master SYBR Green I (Roche) using the following primers:  $p15^{\text{Ink4b}}$ , 5'-ccaatccaggtcatgatgat (forward) and 5'-cgtgcacaggtctgtaag (reverse);  $p19^{\text{Arf}}$ , 5'-gctctggcttctgtaacat (forward) and 5'-tgagcagaagagctgctacg (reverse). Samples were normalized to the levels of *Gapdh* mRNA quantified by qRT-PCR using the following primers: 5'-accacagtcacatccatcac (forward) and 5'-tccaccacctgttctgta (reverse). To quantify the PCR products, a standard curve was created using the PCR products purified with a PCR purification kit (Qiagen), and the DNA concentration was measured with a NanoDrop 2000 spectrophotometer (Thermo Fischer Scientific).

#### Immunohistochemistry

Tissue sections were incubated with primary antibodies against complement C5/C5a (Abbiotec, San Diego, CA) or Ki-67 (Novus Biological, Littleton, CO), and this was followed by detection of antibody binding using a Vector-stain kit (Vector, Burlingame, CA). Tissue sections that were not incubated with the primary antibodies served as negative controls.

#### Immunoblot Analysis

DEN-induced tumor samples were lysed in RIPA buffer, and equal amounts of protein were separated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The blots were probed with antibodies against phospho- and total ERK1/2 (Cell Signaling, Danvers, MA) and Akt (Cell Signaling), *BrafV600E* (Ventana, Tucson, AZ), total *Braf* (Cell Signaling) and C5/C5a. As a loading control,  $\alpha$ -tubulin was detected using anti- $\alpha$ -tubulin antibody (Santa Cruz, Santa Cruz, CA). Band images were acquired using ECL Prime Western Blotting Detection Reagent (GH Healthcare Life Sciences, Pittsburgh, PA) and by exposure of the membranes to X-ray films.

#### Cytokine/Chemokine Array

The expression of cytokines and chemokines was investigated in two DEN-induced hepatic tumors (13 months) and two age-matched normal livers with a Mouse Cytokine Antibody Array Panel A, with loading of 40 types of specific antibodies (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. The reactions were detected by chemiluminescence, and the density of the spots was quantified with ImageJ software and normalized to the positive and negative control spots on the membranes.

#### Statistical Analysis

Statistical analyses were performed using Student's *t*-tests, the Mann-Whitney test or Fischer's exact test by using Prism software (GraphPad, La Jolla, CA), and probability values less than 0.05 were defined as statistically significant.

## RESULTS

#### *BrafV637E* Mutation in DEN-Induced Hepatic Tumors

Whole-exome analysis detected 98 mutations in the four tumors isolated from three mice 13 months after neonatal DEN treatment (Supplementary Table S1). Of these, 96 were missense mutations, one was a six-base deletion, and one was a one-base insertion. Six mutations were detected in all four tumors, three mutations in 3/4 tumors, seven mutations in 2/4 tumors, and 82 mutations in 1/4 tumors (Supplementary Table S1). DEN induces G:C (C:G) to A:T (T:A) transitions via  $\text{O}^6$ -ethyl guanine and T:A (A:T) to C:G (G:C) transitions via  $\text{O}^4$ -ethyl thymine adducts [9]. In the present study, 47 of 96 (48.9%) base change mutations were attributed to  $\text{O}^6$ -ethyl guanine or  $\text{O}^4$ -ethyl thymine adducts. Although not attributable to  $\text{O}^6$ -ethyl guanine or  $\text{O}^4$ -ethyl thymine adducts, 38/96 (39.5%) base change mutations, including the *BrafV637E* mutation (GTG to GAG), were T:A (A:T) to A:T (T:A) transversions, which have been reported to be one of three types of the *H-ras* codon 61 mutations (wild type CAA to AAA, CGA or CTA) in mouse hepatic tumors induced by neonatal treatment with DEN [9].

The A:T to T:A transversion at the 2nd base of codon 637 in the *Braf* gene, which causes a valine to glutamic acid substitution (*BrafV637E*), was detected in all four tumors (Supplemental Table S1). Importantly,

however, no mutations were detected in other known oncogenes or tumor suppressor genes. We then investigated the *BrafV637E* mutation in 17 hepatic tumors isolated from the three mice 13 months after DEN treatment. The *BrafV637E* mutation was detected in 16 (including the 4 samples used for the whole-exome analysis above) of 17 tumors by PCR/direct sequencing (Table 1). Because the *H-ras* codon 61 mutation is frequently observed in DEN-induced mouse liver tumors [10,11], we investigated the mutations in codons 12, 13, and 61 of the *H-ras*, *K-ras* and *N-ras* genes, respectively, in the above 17 tumors. However, other than one *K-ras*G13D mutation in one of the *Braf* mutated tumors, no mutations in these codons were detected in the samples (data not shown).

#### *BrafV637E* Mutation in Microscopic Lesions

We next addressed whether the *BrafV637E* mutation is also common in early DEN-induced lesions. Foci of altered cells were microdissected from the tissue sections from the livers at 5 and 8 months, and the *Braf* mutation was investigated by the PCR direct sequencing method (Figure 1A and B). At 5 months, 16/18 (88.8%) of the foci contained the *BrafV637E* mutation, and at 8 months, 22/28 (78.5%) foci contained the mutation (Table 1); however, the *BrafV637E* mutation was not observed in the non-tumor areas of the same sections (Figure 1B). Therefore, the *BrafV637E* mutation was equally frequent in the hepatic lesions at 5 and 8 months as at 13 months.

Foci of cellular alteration are classified into subtypes (basophilic, acidophilic, mixed cell, clear and amphiphilic) [8], and we therefore investigated the types of lesions that contained the *BrafV637E* mutation. Of 45 foci investigated for the *BrafV637E* mutation, 37 were basophilic, and 8 were eosinophilic. Thirty-six of 37 basophilic foci (97.3%) had the *BrafV637E* mutation, whereas only 1 of 8 (12.5%) eosinophilic foci contained the *BrafV637E* mutation (basophilic vs. eosinophilic foci:  $P < 0.0001$ ) (Figure 1C3).

#### *BrafV637E* Mutation in Spontaneous Hepatic Tumors and in CCl<sub>4</sub>- or DEN/CCl<sub>4</sub>-Induced Hepatic Tumors

We next explored whether the *BrafV637E* mutation is specific to DEN-induced hepatic tumors. For this purpose, the mutation was investigated in spontaneous hepatic lesions and in CCl<sub>4</sub>- or DEN/CCl<sub>4</sub>-induced hepatic tumors in male B6C3F1 mice. None of the 8 spontaneous hepatic lesions (6 foci and 2 HCCs) and none of the 24 CCl<sub>4</sub>-induced hepatic tumors had the mutation, whereas 5/7 (71.4%) of the DEN/CCl<sub>4</sub> tumors had the *BrafV637E* mutation (Table 2). The difference in the frequency of the *BrafV637E* mutation between DEN and spontaneous or CCl<sub>4</sub> lesions was statistically significant ( $P < 0.0001$ ), whereas the difference between DEN and DEN/CCl<sub>4</sub> lesions were not ( $P = 0.3020$ ).

#### Activation of Intracellular Signaling

We investigated whether the *BrafV637E* mutation might activate the downstream ERK1/2 pathway in DEN-induced hepatic tumors. Weak phosphorylation of both ERK1/2 was detected in age-matched normal liver tissue, whereas prominent phosphorylation of ERK1 was observed in DEN-induced tumors isolated 13 months after DEN treatment (Figure 2). Because the PI3K/Akt pathway plays an important role in hepatocarcinogenesis [12–14] and because PI3K/Akt activation can reverse mutated *Braf* oncogene-induced senescence (OIS) [15], we investigated Akt phosphorylation in the DEN-induced hepatic tumors. The phosphorylation of Akt at S473 was increased in the hepatic tumors, whereas phosphorylation at T308 was weakly detected in normal livers but not in hepatic tumors (Figure 2).

#### Expression of Cell-Cycle Regulators

The mutational activation of *Braf* leads to OIS, which is characterized by the overexpression of cell-cycle regulators and may prevent cellular proliferation and induce a cellular senescence phenotype and/or apoptosis [16–18]. We therefore addressed whether the DEN-induced hepatic tumors exhibit OIS by investigating the expression of p15<sup>Ink4b</sup> and p19<sup>Arf</sup>, which play important roles in cell-cycle arrest in mouse cells [19–20]. Quantitative RT-PCR revealed that p15<sup>Ink4b</sup> and p19<sup>Arf</sup> mRNAs were increased in DEN-induced hepatic tumors isolated at 13 months after DEN treatment, whereas no signals for p19<sup>Arf</sup> and p15<sup>Ink4b</sup> mRNAs were detected in the age-matched normal livers after 35 cycles of PCR (Figure 3A and B).

#### Overexpression of Pro-Proliferative/Pro-Survival Cytokines/Chemokines in DEN-Induced Hepatic Tumors

OIS may lead to the senescence-associated secretory phenotype, which is characterized by the increased production of cytokines/chemokines that facilitate cell cycle arrest, apoptosis and immunosurveillance [21,22]. We, therefore, investigated cytokine/chemokine expression in two DEN-induced hepatic tumors 13 months after DEN treatment and in two age-matched normal livers by using a mouse array with antibodies specific to 40 types of cytokines/chemokines. As shown in Figure 4A and B, the expression of complement C5/C5a, intercellular adhesion molecule-1 (ICAM-1), interleukin 1 receptor antagonist (IL-1ra) and chemokine CXCL9 was increased among the 40 factors specifically associated with hepatic tumors, whereas there were no significant differences in the expression levels of other factors between the tumors and age-matched normal livers. The expression of ICAM-1 [23], IL-1ra [24] and CXCL9 [25] has previously been reported in DEN-induced hepatic tumors; however, C5/C5a expression has not been reported. We therefore investigated C5/C5a expression in the hepatic lesions 5 and 8 months




Figure 1. A: *BrafV637E* mutation in microscopic lesions. Focus of cellular alteration (indicated by arrowheads) before (A1) and after (right) microdissection (A2). Scale bars: 100  $\mu$ m. B: *Braf* sequence from non-tumor (NT) and tumor tissues (T). The A:T to T:A transversion at *Braf* codon 637 leads to the *BrafV637E* mutation in the focus (arrow). C: Focus cells with the *BrafV637E* mutation

mainly exhibited basophilic cytoplasm with smaller nuclei (C1), whereas those with wild-type *Braf* mainly displayed acidophilic cytoplasm with large nuclei (C2). Scale bars: 50  $\mu$ m. Thirty-six of 37 basophilic foci contained the *BrafV637E* mutation, whereas only 1/8 acidophilic foci contained the mutation ( $P < 0.0001$ , Fischer's exact test) (C3).

after DEN treatment by immunohistochemistry. Although the surrounding non-tumor hepatocytes exhibited diffuse/weak cytoplasmic staining for C5/C5a, the cells in the foci displayed strong staining in the cytoplasm, presumably in the rough endoplasmic reticulum and Golgi apparatus compartments (Figure 4C and inset). No staining was observed

when the primary antibody was omitted (data not shown).

#### Characteristics of the Liver of Alb-Cre/*BrafV600E* Mice

Alb-Cre/*BrafV600E* mice were normal at birth, but started to die 8 wk after birth. We sacrificed the surviving animals during the period between 8 and




Figure 2. Phosphorylation status of ERK1/2 and Akt in normal liver and DEN-induced tumors at 13 months after neonatal treatment with DEN.  $\alpha$ -tubulin: loading control.

12 wk after birth. The livers of Alb-Cre/*BrafV600E* mice expressed mRNA derived both from normal mouse and mutated human *Braf* exon 15 (Figure 5A and B). The transgenic mice exhibited a 20% decrease in body weight compared with age-matched normal mice, but showed a fivefold-increase in the liver/body weight (Figure 5C, D, and E). Histological examination revealed that the liver consisted entirely of basophilic hepatocytes resembling basophilic foci at 8 wk of birth, and bile duct cells were further increased at 10–12 wk (Figure 5F1-3). The Ki-67 labeling index of hepatocytes in the Alb-Cre/*BrafV600E* mice was 3 times higher than that in normal mice (Figure 5G). Immunoblot analysis revealed that the livers of Alb-Cre/*BrafV600E* mice expressed the *BrafV600E* protein and showed hyperphosphorylation of ERK1 and AktS473 in a manner similar to that observed in DEN-induced hepatic tumors (Figure 6). Furthermore, immunohistochemical staining detected increased C5/C5a expression in the hepatocytes of Alb-Cre/*BrafV600E* mice (Figure 7A). In immunoblot analysis, although C5 levels were not different between age-matched normal and Alb-Cre/*BrafV600E* mice, a band with a smaller molecular weight probably corresponding to C5a was specifically detected in Alb-Cre/*BrafV600E* livers (Figure 7B). There was no difference in hepatic phenotype between male and female Alb-Cre/*BrafV600E* mice.

## DISCUSSION

Whole-exome analysis of four DEN-induced hepatic tumors at 13 months detected 98 mutations; however, with the exception of the *BrafV637E* mutation, no known oncogene or tumor suppressor gene mutations were observed. PCR-direct sequencing of additional DEN-induced lesions, including




Figure 3. A: RT-PCR for p15<sup>Ink4b</sup> and p19<sup>Arf</sup> mRNA in non-tumor livers (NT), hepatic tumors (T), a negative control (distilled water: DW) and a positive control (PCR product used as template: PC). A total of 35 cycles of PCR were performed. MW: molecular weight marker. B: p15<sup>Ink4b</sup> and p19<sup>Arf</sup> mRNA levels were determined by qRT-PCR of DEN-induced hepatic tumors ( $n=9$ ) 13 months after neonatal DEN treatment and in age-matched normal livers ( $n=8$ ).

microscopic foci and grossly visible tumors, revealed that 54/63 (85.7%) lesions had the *BrafV637E* mutations. Although some mutations might be passenger mutations, other mutations, particularly those detected in two or more tumors, might function as oncogenic drivers. In the hepatocarcinogenesis model induced by neonatal DEN treatment, individual DEN-induced tumors grow at different rates, and only a small fraction of preneoplastic lesions eventually progress to HCC [2]. Therefore, it is possible that some mutations may contribute to tumor progression in cooperation with the *BrafV637E* mutation.

The *BrafV637E* mutation was not detected in the spontaneous and CCl<sub>4</sub>-induced tumors but was detected in the tumors induced by neonatal DEN treatment followed by repeated CCl<sub>4</sub> treatment, suggesting that the mutation was dependent on the genotoxic action of DEN. Further supporting this conclusion, 47/96 (48.9%) of the base-change mutations detected by whole-exome analysis were attributable to O<sup>6</sup>-ethyl guanine and O<sup>4</sup>-ethyl thymine, mutagenic adducts generated by DEN [9]. O<sup>6</sup>-ethyl guanine can form a G:T mismatch pair instead of a G:C pair, leading to G:C (C:G) to A:T (T:A) transition, whereas O<sup>4</sup>-ethyl thymine can mismatch with guanine instead of adenine, leading to the T:A (A:T) to C:G (G:C) transition [9]. Furthermore, although not attributable to O<sup>6</sup>-ethyl guanine or O<sup>4</sup>-ethyl thymine, 38/96 (39.5%) of the base-change mutations, including the *BrafV637E* mutation (GTTG to GAG), were T:A (A:T) to A:T (T:A) transversions. The A:T to T:A transversion has been detected as one of three types of the *H-ras* codon 61 mutations (wild-type CAA to CTA)




Figure 4. A: The cytokine/chemokine array analysis used a membrane to load the antibodies individually against 40 types of mouse cytokines/chemokines. Four factors (1: C5/C5a, 2: ICAM-1, 3: CXCL9, 4: IL-1ra) were increased in hepatic tumors compared with normal livers. +: positive control, -: negative control. B: Densitometric analysis of the above data. The data represent the average values for two normal livers and two DEN-induced hepatic tumors. C: Immunohistochemical staining for C5/C5a in the focus (T) and in the surrounding non-tumor hepatic tissue (NT) (left). Inset: high magnification of the focus cell.






Figure 5. Alb-Cre/BrafV600E mice. A: RT-PCR primers (arrows) targeting mutated human and normal mouse *Braf* exon 15. B: The mutated (A) and normal bases (T) in Alb-Cre/BrafV600E mice (arrow in the right panel). C: Livers of normal and Alb-Cre/BrafV600E mice (C). D: Body weight of normal (n: 10 males, 10 females) and Alb-Cre/BrafV600E mice (n: 20 males, 20 females). E: Liver weight relative to body weight in normal (n: 10 males, 10 females) and Alb-Cre/BrafV600E mice (n: 20 males, 20 females). \* $P < 0.01$ . F: Histology of the liver in normal (F1) and Alb-Cre/BrafV600E mice at 8 wk (F2) and 12 wk after birth (F3). Scale bars: 50  $\mu$ m. G: The Ki-67 labeling index of hepatocytes in normal (n = 5) and Alb-Cre/BrafV600E mice (n = 6). \* $P < 0.05$ .




Figure 6. Expression of the BrafV600E protein and the phosphorylation status of ERK1/2 and Akt in the liver of normal and Alb-Cre/*BrafV600E* mice.

in DEN-induced mouse hepatic tumors, together with the CAA to AAA (not attributable to O<sup>6</sup>-ethyl guanine or O<sup>4</sup>-ethyl thymine) and CAA to CGA mutations (attributable to O<sup>4</sup>-ethyl thymine) [9]. Thus, the *Braf* V637E mutation (G<sub>T</sub>G to G<sub>A</sub>G) may be generated by an unknown mechanism similar to that resulting in the *H-ras* codon 61 CAA to CTA mutation.

The *Braf*V637E mutation may lead to activation of the MAPK pathway. In the present study, although total ERK1/2 protein levels did not differ between normal livers and hepatic tumors, phosphorylation of ERK1 was increased in hepatic tumors, whereas both ERK1/2 were weakly phosphorylated in normal livers. Although the exact mechanism of hyperphosphorylation of ERK1 remains unclear, ERK1 may play a primary role in the activation of MAPK pathway. On the other hand the phosphorylation of Akt at S473 was increased in the hepatic tumors. Activation of the PI3K/Akt pathway has been reported to reverse OIS caused by the *Braf* mutation [15], and thus Akt activation may play a significant role in DEN-induced hepatocarcinogenesis. Although the mechanism of Akt phosphorylation requires further investigation, an unknown signaling pathway linked to the *Braf*V637E mutation and/or the autocrine factors generated by the hepatic tumor cells may play a role, as discussed below.

The mRNAs of p15<sup>Ink4b</sup> and p19<sup>Arf</sup> were detected in the hepatic tumors, but not in normal livers, suggesting that the *Braf*V637E mutation activates the OIS-signaling pathways along with pro-proliferative/survival pathways. We have previously demonstrated that the cyclin-dependent kinase inhibitor





Figure 7. A: C5/C5a immunohistochemical staining in the livers of Alb-Cre/*BrafV600E* mice. Scale bar: 10  $\mu$ m. B: Immunoblot analysis of C5/C5a in the livers of normal and Alb-Cre/*BrafV600E* mice.

p27<sup>Kip1</sup> is overexpressed in DEN-induced hepatic tumors and that the BrdU labeling index is quite low in early tumors, indicating a slow rate of proliferation [12]. Because grossly visible tumors are not usually observed until 6–8 months after treatment with DEN in our experimental model, the growth of *Braf*V637E-mutated cells may be suppressed for a long period. Cyclin-dependent kinase inhibitors, such as p15<sup>Ink4b</sup>, p19<sup>Arf</sup>, and p27<sup>Kip1</sup>, may counteract the *Braf*V637E-induced pro-proliferative signals, contributing to the dormancy of *Braf*V637E-mutated cells.

Cytokines/chemokines that participate in sustained cell proliferation, insensitivity to apoptosis and escape from immunosurveillance in cancer, such as C5/C5a, ICAM-1, IL-1ra, and CXCL9, were increased in the DEN-induced hepatic tumors, whereas factors that promote OIS, such as IL-1 $\alpha$ ,  $\beta$ , IL-6, INF $\gamma$ , and TNF $\alpha$  [21,22] were not increased. Kang et al. [26] have reported that introduction of the *N-ras*G12V mutation into mouse hepatocytes in vivo leads to OIS, which in turn causes the OIS-induced secretory phenotype. The chemokines and cytokines such as CTACK, IL-1 $\alpha$ , leptin, MCP1, and RANTES generated by N-rasG12V expressing hepatocytes recruit inflammatory cells that contribute to clearance of the N-rasG12V expressing hepatocytes. In the present study, however, we did not observe any inflammatory response against preneoplastic/neoplastic hepatocytes, and thus it is possible that the lesions that we investigated might have

somehow escaped from the inflammatory attack in an early stage.

C5a, a C5 convertase-cleaved product of C5, activates the PI3K-Akt pathway via its receptor C5aR, which is involved in various tumor phenotypes, including cell proliferation, insensitivity to apoptosis, angiogenesis and escape from immunosurveillance [27,28]. Furthermore, C5-deficient mice exhibit impaired liver regeneration after partial hepatectomy [29]. ICAM-1 is overexpressed in DEN-induced rat hepatic tumor cells [23] and in human HCC cells [30], and levels of the secreted form sICAM-1 are increased in the serum of HCC patients [31,32]. ICAM-1 promotes metastasis via cell/cell and cell/extracellular matrix adhesion in cancer cells [33], and sICAM-1 is thought to inhibit the interaction between tumor cells and immune cells, enabling escape from immunosurveillance [34]. Our group has previously demonstrated overexpression of IL-1ra, which antagonizes the functions of IL-1 $\alpha$ ,  $\beta$ , in DEN-induced hepatic tumors [24], and an increase in IL-1ra over IL-1 $\alpha$ ,  $\beta$  contributes to tumor growth [35,36]. CXCL9 is reportedly upregulated in livers containing DEN-induced hepatic tumors in mice [25], and CXCL9 is excreted by tumor cells and subsequently recruits immune cells that express its receptor (CXCR3) towards the tumors. However, the CXCL9-CXCR3 interaction can attenuate tumor immunity and produce pro-tumorigenicity, depending on the tumor type [37]. Furthermore, CXCL9 directly promotes invasion/infiltration via CXCR3 on HCC cells in vitro [38]. In addition, our previous studies, together with those of other groups, have demonstrated that DEN-induced hepatic tumor cells produce a number of growth factors, such as TGF- $\alpha$  [39], insulin-like growth factor II [40], VEGF [13] and NGF [41]. Thus, the autocrine pro-proliferative/survival factors produced by the hepatic tumor cells may provide a selective advantage by accumulating within the tumor microenvironment. Additional studies are needed to clarify the relevance of autocrine factors to the *BrafV637E* mutation.

The transgenic mice expressing human *BrafV600E*, which corresponds to mouse *BrafV637E*, in the liver under control of the albumin/enhancer/promoter exhibited a 5-fold increase in liver/body weight ratio, and the liver consisted entirely of small basophilic hepatocytes mimicking those observed in basophilic foci induced by DEN. Furthermore, the liver exhibited hyperphosphorylation of ERK1 and AktS473 and increased expression of C5/C5a. Thus, the expression of *BrafV637E* protein is sufficient to induce the hepatocytic changes observed in DEN-induced hepatic tumors. However, the Alb-Cre/*BrafV600E* mice started to die 8 wk after birth, and most died by 12 wk. A similar phenomenon has previously been reported for the transgenic mice with liver-specific *H-ras* expression under control of the albumin enhancer/promoter [42]. The possibility that aberrant activation

of *Braf*, and presumably also *H-ras*, in the liver causes fatal systemic disease(s) is now under investigation in our laboratory.

#### ACKNOWLEDGMENTS

This study was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology and grants from the Asahikawa Medical University Advanced Science Research Program. We are grateful to Dr. Takuji Tanaka of the Tokai Cell Institute for providing spontaneous mouse hepatic tumor samples.

#### REFERENCES

- Mittal S, Serag EI. Epidemiology of hepatocellular carcinoma. *J Clin Gastroenterol* 2013;47:S2-S6.
- Vesselinovich SD, Mihailovich N, Rao KV. Morphology and metastatic nature of induced hepatic nodular lesions in C57BL x C3H F1 mice. *Cancer Res* 1978;38:2003-2010.
- Maronpot RR, Fox T, Malarkey DE, Goldsworthy TL. Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. *Toxicology* 1995;101:125-156.
- Buchmann A, Karcier Z, Schmid B, Strathmann J, Schwarz M. Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis. *Mutat Res* 2008;638:66-74.
- Pakneshan S, Salajegheh A, Smith RA, Lam AK-Y. Clinicopathological relevance of BRAF mutations in human cancer. *Pathology* 2013;45:346-356.
- Huff JE, McConnell EE, Haseman JK, et al. Carcinogenesis studies: Results of 398 experiments on 104 chemicals from the U.S. National Toxicology Program. *Ann N Y Acad Sci* 1988;534:1-30.
- Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. *Genes Dev* 2007;21:379-384.
- Thoolen B, Maronpot RR, Harada T, et al. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. *Toxicol Pathol* 2010;38:55-81S.
- Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: Bioactivation, DNA-adduct formation, mutagenicity, and initiation. *Pharmacol Ther* 1996;71:57-81.
- Buchmann A, Bauer-Hofmann R, Mahr J, Drinkwater NR, Luz A, Schwarz M. Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: Correlation with susceptibility to hepatocarcinogenesis. *Proc Natl Acad Sci USA* 1991;88:911-915.
- Dragani TA, Manenti G, Colombo BM, et al. Incidence of mutations at codon 61 of the Ha-ras gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis. *Oncogene* 1991;6:333-338.
- Yamamoto M, Tamakawa S, Yoshie M, Yaginuma Y, Ogawa K. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. *Mol Carcinog* 2006;45:901-913.
- Tanaka H, Yamamoto M, Hashimoto N, et al. Hypoxia-independent overexpression of hypoxia-inducible factor 1 as an early change in mouse hepatocarcinogenesis. *Cancer Res* 2006;66:11263-11270.
- Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. *Gastroenterology* 2008;135:1972-1983.
- Vredevelde LCW, Possik PA, Smit MA, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation

- contributes to melanomagenesis. *Genes Dev* 2012;26:1055–1069.
16. Dhomen N, Reis-Filho JS, Dias S, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. *Cancer Cell* 2009;15:294–303.
  17. Michaloglou C, Vredeveld L, Soengas M, et al. BRAF<sup>E600</sup>-associated senescence-like cell cycle arrest of human naevi. *Nature* 2005;436:720–724.
  18. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. *Nat Rev Cancer* 2006;6:472–726.
  19. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. *Cell* 1997;91:649–659.
  20. Latres E, Malumbres M, Sotillo R, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. *EMBO J* 2000;19:3496–3506.
  21. Bartek J, Hodny Z, Lukas J. Cytokine loops driving senescence. *Nat Cell Biol* 2008;10:1–3.
  22. Tchkonja T, Zhu Y, van Deursen J, Campisi J, Kirkland J. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. *J Clin Invest* 2013;123:966–972.
  23. Matsuoka S, Matsumura H, Arakawa Y, et al. Expression of intercellular adhesion molecule-1 in the livers of rats treated with diethylnitrosamine. *J Clin Biochem Nutr* 2009;45:137–143.
  24. Yamada Y, Karasaki H, Matsushima K, Lee GH, Ogawa K. Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis. *Lab Invest* 1999;79:1059–1067.
  25. Schneider C, Teufel A, Yevsa T, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. *Gut* 2012;61:1733–1743.
  26. Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature* 2011;479:547–551.
  27. Cho MS, Vasquez HG, Rupaimoole R, et al. Autocrine effects of tumor-derived complement. *Cell Reports* 2014;6:1085–1095.
  28. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. *Mol Cancer Res* 2010;8:1453–1465.
  29. Strey CW, Markiewski M, Mastellos D, et al. The pro-inflammatory mediators C3a and C5a are essential for liver regeneration. *J Exp Med* 2003;198:913–923.
  30. Momosaki S, Yano H, Ogasawara S, Higaki K, Hisaka T, Kojiro M. Expression of intercellular adhesion molecule 1 in human hepatocellular carcinoma. *Hepatology* 1995;22:1708–1713.
  31. Zöhrens G, Armbrust T, Pirzer U, Meyer zum Büschenfelde KH, Ramadori G. Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: Relationship to disease activity and cirrhosis. *Hepatology* 1993;18:798–802.
  32. Shimizu Y, Minemura M, Tsukishiro T, et al. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. *Hepatology* 1995;22:525–531.
  33. Hayes SH, Seigel GM. Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. *Int J Clin Exp Pathol* 2009;2:553–560.
  34. Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): An overview. *Eur Cytokine Netw* 2004;15:91–98.
  35. La E, Rundhaug JE, Fischer SM. Role of intracellular interleukin-1 receptor antagonist in skin carcinogenesis. *Mol Carcinog* 2001;30:218–223.
  36. Arend WP. The balance between IL-1 and IL-1Ra in disease. *Cytokine Growth Factor Rev* 2002;13:323–340.
  37. Billottet C, Quemener C, Bikfalvi A. CXCR3, a double-edged sword in tumor progression and angiogenesis. *Biochim Biophys Acta* 2013;1836:287–295.
  38. Lan X, Xiao F, Ding Q, et al. The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2. *J Mol Histol* 2014;45:689–696.
  39. Tanno S, Ogawa K. Abundant TGF $\alpha$  precursor and EGF receptor expression as a possible mechanism for the preferential growth of carcinogen-induced preneoplastic and neoplastic hepatocytes in rats. *Carcinogenesis* 1994;15:1689–1694.
  40. Ishizaki T, Yoshie M, Yaginuma Y, Tanaka T, Ogawa K. Loss of Igf2 imprinting in monoclonal mouse hepatic tumor cells is not associated with abnormal methylation patterns for the H19, Igf2, and Kvlqt1 differentially methylated regions. *J Biol Chem* 2003;278:6222–6228.
  41. Kishibe K, Yamada Y, Ogawa K. Production of nerve growth factor by mouse hepatocellular carcinoma cells and expression of TrkA in tumor-associated arteries in mice. *Gastroenterology* 2002;122:1978–1986.
  42. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL. Oncogene-induced liver neoplasia in transgenic mice. *Oncogene* 1989;4:715–724.

#### SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.